TY - JOUR
T1 - Loss of Heterozygosity for Chromosomes 16q and 1p in Wilms’ Tumors Predicts an Adverse Outcome
AU - Grundy, Paul E.
AU - Telzerow, Perry E.
AU - Breslow, Norman
AU - Moksness, Jamie
AU - Huff, Vicki
AU - Paterson, Malcolm C.
PY - 1994/5
Y1 - 1994/5
N2 - We have prospectively analyzed Wilms’ tumors from 232 patients registered on the National Wilms’ Tumor Study for loss of heterozygosity (LOH) on chromosomes 11p, 16q, and 1p. These chromosomal aberrations were found in 70 (33%), 35 (17%), and 21 (12%) of the informative cases, respectively. LOH for two of these regions occurred in only 25 cases, and only one tumor harbored LOH at all three sites. There was no statistically significant association between LOH at any of the three regions and either the stage or histological classification of the tumor. Patients with tumorspecific LOH for chromosome 16q had relapse rates 33 times higher (P = 0.01) and mortality rates 12 times higher (P < 0.01) than patients without LOH for chromosome 16q. These differences remained when adjusted for histology or for stage. Patients with LOH for chromosome 1p had relapse and mortality rates three times higher than those for patients without LOH for chromosome 1p, but these results were not statistically significant In contrast, LOH for chromosome 11p had no effect on measures of outcome. These molecular markers may serve to further stratify Wilms’ tumor patients into biologically favorable and unfavorable subgroups, allowing continued use of the clinical trial mechanism in the study of Wilms’ tumor.
AB - We have prospectively analyzed Wilms’ tumors from 232 patients registered on the National Wilms’ Tumor Study for loss of heterozygosity (LOH) on chromosomes 11p, 16q, and 1p. These chromosomal aberrations were found in 70 (33%), 35 (17%), and 21 (12%) of the informative cases, respectively. LOH for two of these regions occurred in only 25 cases, and only one tumor harbored LOH at all three sites. There was no statistically significant association between LOH at any of the three regions and either the stage or histological classification of the tumor. Patients with tumorspecific LOH for chromosome 16q had relapse rates 33 times higher (P = 0.01) and mortality rates 12 times higher (P < 0.01) than patients without LOH for chromosome 16q. These differences remained when adjusted for histology or for stage. Patients with LOH for chromosome 1p had relapse and mortality rates three times higher than those for patients without LOH for chromosome 1p, but these results were not statistically significant In contrast, LOH for chromosome 11p had no effect on measures of outcome. These molecular markers may serve to further stratify Wilms’ tumor patients into biologically favorable and unfavorable subgroups, allowing continued use of the clinical trial mechanism in the study of Wilms’ tumor.
UR - http://www.scopus.com/inward/record.url?scp=0028351728&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028351728&partnerID=8YFLogxK
M3 - Article
C2 - 8162576
AN - SCOPUS:0028351728
SN - 0008-5472
VL - 54
SP - 2331
EP - 2333
JO - Cancer Research
JF - Cancer Research
IS - 9
ER -